Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mantle Cell Lymphoma
98%
Ibrutinib
26%
Lymphoma Cells
20%
Cyclin-dependent Kinase 9 (CDK9)
18%
Bruton Tyrosine Kinase Inhibitor
17%
NF-B
17%
Epidermal Growth Factor Receptor
15%
Tumor Progression
14%
Venetoclax
14%
Overcoming Resistance
14%
Lymphoma Patients
14%
CARMA3
14%
Bruton's Tyrosine Kinase
12%
Nuclear factor-κB
12%
Tumor-immune System
12%
Immune Evolution
12%
Molecular Heterogeneity
12%
Single-cell Profiling
12%
Chemotherapy Resistance
12%
Ibrutinib Resistance
9%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
Signal Component
7%
Co-target
7%
Bioinformatics Analysis
7%
MALT1
7%
Apoptosis Repressor with Caspase Recruitment Domain
7%
Phosphoinositide 3-kinase (PI3K)
7%
Tumor Cells
7%
Heat Shock Protein 90 (Hsp90)
6%
Structural Optimization
6%
Chimeric Antigen Receptor T-cell Therapy
6%
Inflammatory Response
6%
B-cell Lymphoma 2 (Bcl-2)
6%
Cell Adhesion
6%
Pirtobrutinib
6%
Apoptosis
6%
Lethality
6%
Mycobiota
6%
Glutaminase 1 (GLS1)
6%
B-cell Receptor Signaling
6%
Arrhythmogenic Right Ventricular Dysplasia
6%
Transmembrane Protein 43
6%
TMEM43
6%
Innate Immunity
6%
High Risk
6%
Receptor 1
6%
Outcome Profiles
6%
Dual Inhibition
6%
Rac2
6%
Potentiation
6%
Medicine and Dentistry
Mantle Cell Lymphoma
100%
Ibrutinib
29%
Neoplasm
18%
Bruton Tyrosine Kinase
18%
Mantle Cell Lymphoma Cell
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
15%
Cell Line
15%
Programmed Cell Death
14%
Bruton Tyrosine Kinase Inhibitor
13%
Venetoclax
13%
Cyclin-Dependent Kinase 9
12%
Chimeric Antigen Receptor T-Cell
11%
Xenograft
8%
Chimeric Antigen Receptor
7%
Mantle Cell Lymphoma Cell Line
7%
Cell Adhesion
7%
Lethality
7%
Antineoplastic Activity
7%
Receptor
7%
In Vitro
6%
Cell Signaling Pathway
6%
Glutaminase
6%
B Lymphocyte Receptor
6%
Protein Kinase B
6%
Inhibitor of Apoptosis Protein
6%
Cancer
6%
Protein Kinase B Inhibitor
6%
Mycosis
6%
Innate Immunity
6%
T Cell
6%
Cancer Therapy
6%
Downregulation
6%
Deacetylation
6%
Antibody-Drug Conjugate
6%
Tumor Cell
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Histone
6%
Myeloma
6%
Malignant Neoplasm
6%
Immunity
6%
Personalized Medicine
6%
Citric Acid Cycle
6%
Oncology
6%
Hematology
6%
Biochemistry, Genetics and Molecular Biology
Bruton Tyrosine Kinase
33%
Epidermal Growth Factor Receptor
25%
Cyclin-Dependent Kinase 9
25%
Tyrosine Kinase Inhibitor
20%
Tumor Progression
17%
Ibrutinib
17%
T Cell
15%
Immunity
14%
Genomics
12%
Chimeric Antigen Receptor
12%
SMARCA4
8%
Exome Sequencing
8%
Innate Immunity
7%
Bioinformatics
7%
Cancer Cell
7%
Glutaminase
6%
MALT1
6%
TMEM43
6%
DNA Binding
6%
Membrane Protein
6%
Transmembrane Protein
6%
Endoplasmic Reticulum Stress
6%
Complement Factor B
6%
Mucosa
6%
BCL10
6%
Immunoglobulin Enhancer Binding Protein
6%
Herpes Simplex Virus
6%
DNA Synthesis
6%
Histone
6%
Epidermal Growth Factor
6%
CD23
6%
Deacetylation
6%
Rituximab
6%
Arginine
6%
Dysplasia
6%
Gene Mutation
6%
Citric Acid Cycle
6%
Mouse Model
5%
Reprogramming
5%
CD19
5%
IC50
5%
